Kiniksa Pharmaceuticals International, plc
Moat Score — Kiniksa Pharmaceuticals International, plc
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Kiniksa holds FDA approval and Orphan Drug designation (KPL-387, granted October 2025) tied specifically to recurrent pericarditis, and states it is unaware of any other FDA-approved therapy for that indication. This regulatory/IP position is real but narrower than a broad patent estate, since the underlying IL-1 mechanism is already commercialized by others (Novartis's canakinumab, AbbVie's lutikizumab) in adjacent diseases. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Kiniksa has no manufacturing or scale cost advantage; it licenses rilonacept drug substance production (currently transferring from Regeneron to Samsung Biologics) and shares half of U.S. ARCALYST profits with Regeneron, which caps rather than enhances its cost position relative to a fully integrated competitor. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the only FDA-approved therapy specifically for recurrent pericarditis, Kiniksa has demonstrated real pricing power, evidenced by ARCALYST revenue nearly doubling to $677.6 million in FY2025 while net income swung from a loss to $59.0 million. That power is bounded by payer/reimbursement pressure and the approaching entry of VTX2735 (soon Eli Lilly-backed) and oral CardiolRx. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Kiniksa's business; ARCALYST's value to one patient or prescriber does not increase with the number of other patients or prescribers using it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physicians and patients who have stabilized a recurrent pericarditis treatment regimen on ARCALYST face some inertia to switching given the condition's painful relapse risk, and the Kiniksa OneConnect patient support program reinforces adherence, but switching costs are not contractual or structural the way they would be in, say, enterprise software. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The estimated U.S. addressable population of about 40,000 recurrent pericarditis patients (roughly 14,000 in the initial focus group) is a modestly sized orphan market that may not comfortably support multiple well-capitalized competitors long-term, but it is not so small or capital-intensive that a deep-pocketed entrant like Eli Lilly (via its planned Ventyx acquisition) would be deterred from entering. |